[1] STASI C, SILVESTRI C, VOLLER F. Emerging trends in epidemiology of hepatitis B virus infection[J].J Clin Transl Hepatol, 2017,5(3):272-276. [2] LIU Z, YANG Q, SHI O, et al. The epidemiology of hepatitis B and hepatitis C infections in China from 2004 to 2014:An observational population-based study[J].J Viral Hepat, 2018,25(12):1543-1554. [3] NANNINI P, SOKAL E M. Hepatitis B:changing epidemiology and interventions[J].Arch Dis Child, 2017,102(7):676-680. [4] LU BR, ZHANG B C, WANG L C,et al. Hepatitis B virus e antigen regulates monocyte function and promotes B lymphocyte activation[J].Viral Immunol, 2017,30(1):35-44. [5] TANG J, FEI J Q, GU C X,et al. The influence of B and T lymphocyte attenuator genetic variants on susceptibility to chronic hepatitis B virus infection[J]. Cell Physiol Biochem,2018,45(6):2540-2547. [6] 中华医学会传染病与寄生虫病学分会,肝病学分会. 病毒性肝炎防治方案[J].中华肝脏病杂志, 2010, 12(6):324-326. [7] ARENDS J E, LIEVELD F I, AHMAD S, et al. New viral and immunological targets for hepatitis B treatment and cure:A review[J]. Infect Dis Ther, 2017,6(4):461-476. [8] LOBAINA Y, MICHEL M L. Chronic hepatitis B:immunological profile and current therapeutic vaccines in clinical trials[J]. Vaccine,2017,35(18):2308-2314. [9] PAPASTERGIOU V,LOMBARDI R,MACDONALD D,et al. Global epidemiology of hepatitis B virus (HBV) infection[J].Curr Hepatol Rep,2015,14(3):171-178. [10] WIGGINS B G, STAMATAKI Z, LALOR P F,et al. Using ex vivo liver organ cultures to measure lymphocyte trafficking[J].Methods Mol Biol, 2017, 1591:177-194. [11] KLEINE M, RAMACKERS W, TIMROTT K, et al. Hepatocyte-induced CD4+ T cell alloresponse is associated with major histocompatibility complex class Ⅱ up-regulation on hepatocytes and suppressible by regulatory T cells[J].Liver Transpl, 2018,24(3):407-419. [12] POLARIS OBSERVATORY COLLABORATORS.Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016:a modelling study[J].Lancet Gastroenterol Hepatol, 2018,3(6):383-403. [13] TANG L S Y, COVERT E. Chronic hepatitis B infection:A review[J].JAMA, 2018,319(17):1802-1813. [14] DEL CAMPO J A, GALLEGO P, GRANDE L.Role of inflammatory response in liver diseases:Therapeutic strategies[J].World J Hepatol, 2018, 10(1):1-7. [15] KARRA V K, CHOWDHURY S J,RUTTALA R,et al. Clinical significance of quantitative HBsAg titres and its correlation with HBV DNA levels in the natural history of hepatitis B virus infection[J].J Clin Exp Hepatol, 2016, 6(3):209-215. [16] YOU J,YAN Y Z,SRIPLUNG H,et al. Decline of hepatitis B virus load correlate with increase of Th1/Th2 immunity in chronic hepatitis B patients during long-term treatment with entecavir[J].Int J Infect Dis, 2014, 21(S1):320-325. [17] TIAN Z F,YOU Z L,YI H,et al.Effect of entecavir on CD4+ T-cell subpopulations in patients with chronic hepatitis B[J].Ann Hepatol, 2016, 15(2):174-182. [18] ZHANG J Z,FENG W T.Dynamic changes of Th1/Th2 type cytokines in peripheral blood in patients with HBeAg-positive chronic hepatitis B during telbivudine therapy[J].J Pract Med. 2013, 13(4):111-116. [19] GAO F Y, SUN L, YE X, et al. Development and validation of a prognostic model for acute-on-chronic hepatitis B liver failure[J]. Eur J Gastroenterol Hepatol, 2017,29(6):669-678. [20] GONG Y.Changes of peripheral blood T lymphocyte subsets and serum cytokine levels in patients with chronic hepatitis B receiving lamivudine and kurorinone treatment[J].J Clin Hepatol, 2013, 16(7):37-45. [21] LI X F, LIU X, TIAN L,et al. Cytokine-mediated immunopathogenesis of hepatitis B virus infections[J]. Clin Rev Allergy Immunol, 2016,50(1):41-54. |